198 related articles for article (PubMed ID: 21886191)
1. Vesicular stomatitis virus as a treatment for colorectal cancer.
Stewart JH; Ahmed M; Northrup SA; Willingham M; Lyles DS
Cancer Gene Ther; 2011 Dec; 18(12):837-49. PubMed ID: 21886191
[TBL] [Abstract][Full Text] [Related]
2. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.
Blackham AU; Northrup SA; Willingham M; D'Agostino RB; Lyles DS; Stewart JH
Surgery; 2013 Mar; 153(3):333-43. PubMed ID: 23102637
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors.
Randle RW; Northrup SA; Sirintrapun SJ; Lyles DS; Stewart JH
Surgery; 2013 Dec; 154(6):1323-29; discussion 1329-30. PubMed ID: 23973113
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.
Ahmed M; Puckett S; Lyles DS
Cancer Gene Ther; 2010 Dec; 17(12):883-92. PubMed ID: 20725101
[TBL] [Abstract][Full Text] [Related]
5. Cell Cycle Arrest in G
Bressy C; Droby GN; Maldonado BD; Steuerwald N; Grdzelishvili VZ
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487274
[TBL] [Abstract][Full Text] [Related]
6. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
[TBL] [Abstract][Full Text] [Related]
7. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.
Blackham AU; Northrup SA; Willingham M; Sirintrapun J; Russell GB; Lyles DS; Stewart JH
J Surg Res; 2014 Apr; 187(2):412-26. PubMed ID: 24252853
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68.
Ehrig K; Kilinc MO; Chen NG; Stritzker J; Buckel L; Zhang Q; Szalay AA
J Transl Med; 2013 Mar; 11():79. PubMed ID: 23531320
[TBL] [Abstract][Full Text] [Related]
9. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers.
Fehl DJ; Ahmed M
Virus Res; 2017 Jan; 228():14-23. PubMed ID: 27865863
[TBL] [Abstract][Full Text] [Related]
10. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
11. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
Betancourt D; Ramos JC; Barber GN
J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
[TBL] [Abstract][Full Text] [Related]
12. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus.
Zhang P; Han X; Tan W; Chen D; Sun Q
Thorac Cancer; 2023 Jan; 14(3):246-253. PubMed ID: 36447430
[TBL] [Abstract][Full Text] [Related]
13. Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis From Colon Cancer.
Day GL; Bryan ML; Northrup SA; Lyles DS; Westcott MM; Stewart JH
J Surg Res; 2020 Jan; 245():127-135. PubMed ID: 31415934
[TBL] [Abstract][Full Text] [Related]
14. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
15. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN
J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
[TBL] [Abstract][Full Text] [Related]
17. rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.
Wu L; Huang TG; Meseck M; Altomonte J; Ebert O; Shinozaki K; García-Sastre A; Fallon J; Mandeli J; Woo SL
Hum Gene Ther; 2008 Jun; 19(6):635-47. PubMed ID: 18533893
[TBL] [Abstract][Full Text] [Related]
18. [Vesicular stomatitis virus in the fight against cancer].
Janelle V; Poliquin L; Lamarre A
Med Sci (Paris); 2013 Feb; 29(2):175-82. PubMed ID: 23452604
[TBL] [Abstract][Full Text] [Related]
19. Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.
Heiber JF; Barber GN
J Virol; 2011 Oct; 85(20):10440-50. PubMed ID: 21813611
[TBL] [Abstract][Full Text] [Related]
20. The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.
Janelle V; Langlois MP; Lapierre P; Charpentier T; Poliquin L; Lamarre A
Mol Ther; 2014 Jun; 22(6):1198-1210. PubMed ID: 24590047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
